Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...